What is the appropriate dosage of rivaroxaban (Xarelto) for supraventricular tachycardia (SVT)?

Xarelto (Rivaroxaban) is NOT indicated for supraventricular tachycardia (SVT)

Rivaroxaban has no role in the treatment of SVT—this is a fundamental misunderstanding of the condition and the medication. SVT is a cardiac arrhythmia requiring rate/rhythm control, not anticoagulation.

Why This Question Reflects a Clinical Misunderstanding

SVT is treated with:

• Acute management: Vagal maneuvers (modified Valsalva maneuver - 43% effective) followed by IV adenosine (91% effective) 1, 2
• Rate control agents: Beta-blockers, diltiazem, or verapamil for ongoing management 1, 2
• Definitive therapy: Catheter ablation (94.3-98.5% success rate) 3

Rivaroxaban (Xarelto) is an anticoagulant used for:

• Atrial fibrillation: 20 mg once daily (15 mg if CrCl 15-50 mL/min) 4, 5
• Venous thromboembolism: 15 mg twice daily for 21 days, then 20 mg once daily 6, 7
• Superficial vein thrombosis: 10 mg once daily 8, 7

Critical Clinical Distinction

SVT ≠ Atrial Fibrillation

You may be confusing SVT with atrial fibrillation, which DOES require anticoagulation for stroke prevention. The guidelines are explicit that SVT management focuses on terminating the arrhythmia and preventing recurrence through rate control or ablation—not anticoagulation 1, 2.

Correct SVT Management Algorithm

For acute hemodynamically stable SVT:

1. Modified Valsalva maneuver first 1
2. IV adenosine 6 mg rapid push (can repeat 12 mg twice) 1, 2
3. If refractory: IV diltiazem 15-20 mg or verapamil 2.5-5 mg 1, 2
4. Synchronized cardioversion if pharmacologic therapy fails 1, 2

For ongoing management:

• First-line: Catheter ablation (curative in >94% of cases) 1, 3
• Alternative: Oral beta-blockers, diltiazem, or verapamil 1, 2

There is no dosage of Xarelto for SVT because anticoagulation is not part of SVT treatment.